Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

KalVista Pharmaceuticals Ltd.

Home Clinical Trial Sponsors and OrganizationsKalVista Pharmaceuticals Ltd.

KalVista Pharmaceuticals Ltd.

ACTIVE

United Kingdomwww.kalvista.comSubsidiary

Part of KalVista Pharmaceuticals

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

33

30 active

Approvals

1

Total approvals

Agencies

1

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

29

87.9%

Phase 3

4

12.1%

Trial Status Distribution

Active, not recruiting

29

87.9%

Completed

1

3.0%

Not yet recruiting

1

3.0%

Recruiting

2

6.1%

Clinical Trials

Trials sponsored by this organization (33)

A study to evaluate if different doses of KVD900 are safe and effective in treating attacks in patients with Hereditary Angioedema.

Active, not recruiting

Jan 2023114 participants

A long-term study to evaluate if KVD900 is safe and effective intreating attacks in patients with Hereditary Angioedema.

Active, not recruiting

Jan 2023150 participants

A long-term study to evaluate if KVD900 is safe and effective intreating attacks in patients with Hereditary Angioedema.

Active, not recruiting

Jan 2023150 participants

A study to evaluate if different doses of KVD900 are safe and effective in treating attacks in patients with Hereditary Angioedema.

Active, not recruiting

Jan 2023136 participants

A long-term study to evaluate if KVD900 is safe and effective in treating attacks in patients with hereditary angioedema

Active, not recruiting

Nov 2022145 participants

A long-term study to evaluate if KVD900 is safe and effective in treating attacks in patients with Hereditary Angioedema.

Oct 2022150 participants

A study to evaluate if different doses of KVD900 are safe and effective in treating attacks in patients with hereditary angioedema

Sep 2022136 participants

A long-term study to evaluate if KVD900 is safe and effective intreating attacks in patients with Hereditary Angioedema.

Active, not recruiting

Aug 2022150 participants

Page 1 of 5

Approvals

Approvals by Agency

FDA

Food and Drug Administration

1

Approvals

Recent Approvals

News

No news articles found

On this page

Overview
Clinical Trials33
Approvals1
News

Back to Organizations